Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article, J Nanomater Mol Nanotechnol Vol: 3 Issue: 1
IG-001 - A Non-Biologic Nanoparticle Paclitaxel for the Treatment of Solid Tumors
| Kouros Motamed*, Yin Goodman, Larn Hwang, Chao Hsiao and Vuong Trieu |
| IGDRASOL Inc. One Technology Dr. Suite J-729, Irvine, CA, USA |
| Corresponding author : Dr. Kouros Motamed IGDRASOL Inc. One Technology Dr. Suite J-729, Irvine, CA 92618, USA Tel: 1-949-988-7920; Fax: 1-949-988-7927 E-mail: kmotamed@sorrentotherapeutics.com |
| Received: October 22, 2013 Accepted: January 07, 2014 Published: January 07, 2014 |
| Citation: Motamed K, Goodman Y, Hwang L, Hsiao C, Trieu V (2014) IG-001 - A Non-Biologic Nanoparticle Paclitaxel for the Treatment of Solid Tumors. J Nanomater Mol Nanotechnol 3:1. doi:10.4172/2324-8777.1000136 |
Abstract
IG-001 - A Non-Biologic Nanoparticle Paclitaxel for the Treatment of Solid Tumors
nab-paclitaxel (Abraxane®)—a Cremophor-free, albumin-bound, nanoparticle form of paclitaxel—though a breakthrough in paclitaxel formulation, has inherent problems associated with any biologics. IG-001 (Genexol-PM®), a polymeric micellar formulation forms nanoparticles with paclitaxel containing a hydrophobic core and a hydrophilic shell and is being developed as the next generation nanoparticle paclitaxel. Its target indications are solid tumors including Breast, Lung, Ovarian, Bladder, Melanoma and Pancreatic cancers. Similar to nab-paclitaxel, due to its very fast dissolution in plasma, high tumor/plasma ratio, and dose-proportional PK, IG-001 is a superior alternative to Taxol®. Moreover, despite a lack of serum albumin in its formulation, IG-001 takes full advantage of its ability to rapidly deliver paclitaxel to the targeted tissue via an albuminmediated transport, as previously described for nab-paclitaxel.
